Predatory Medicine: Exploring and Measuring the Vulnerability of Medical AI to Predatory Science

Shalini Saini
Nitesh Saxena
Texas A&M University, College Station, TX, USA

Abstract

Medical Artificial Intelligence (MedAI) for diagnosis, treatment options, and drug development represents the new age of healthcare. The security, integrity, and credibility of MedAI tools are paramount issues because human lives are at stake. MedAI solutions are often heavily dependent on scientific medical research literature as a primary data source that draws the attacker’s attention as a potential target. We present a first study of how the output of MedAI can be polluted with Predatory Publications Presence (PPP).

We study two MedAI systems: mediKanren (Disease independent) and CancerMine (Disease-specific), which use research literature as primary data input from the research repository PubMed, PubMed derived database SemMedDB, and NIH translational Knowledge Graphs (KGs). Our study has a three-pronged focus: (1) identifying the PPP in PubMed; (2) verifying the PPP in SemMedDB and the KGs; (3) demonstrating the existing vulnerability of PPP traversing to the MedAI output.

Our contribution lies in identifying the existing PPP in the MedAI inputs and demonstrating how predatory science can jeopardize the credibility of MedAI solutions, making their real-life deployment questionable.

Data and Code Availability This paper uses the data and code from PubMed, NIH SemMedDB, NIH Translational KGs (provided by mediKauren team), CancerMine Zenodo repository, and mediKanren Github

1. Introduction

The undeniable contribution of Artificial Intelligence (AI) in medicine is reaching new milestones. In 2018, FDA approved IDx-DR as the first human-independent AI system to detect Diabetic Retinopathy, a leading cause of blindness (FDA, 2018). Google’s AI Inception v3 may assist with the early detection of lung cancer, the deadliest cancer, causing 1.7 million deaths per year globally (Shetty, 2019).

MedAI Relevance to Precision Medicine: Precision Medicine is an innovative approach based on an individual’s genetics, health history, environment, and diet. Biomedical research-driven Precision Medicine is promising to provide improved healthcare and lower the overall burden of unknown, delayed, or incorrect diagnosis and treatment (Singh et al., 2017; Tehrani et al., 2013; Thoene, 2021). Precision Medicine relies heavily on data and analytics for its adoption into healthcare (Ginsburg and Phillips, 2018). MedAI assists Precision Medicine by processing a large amount of information from heterogeneous sources in no time.

Impact of Research on MedAI: National Institute of Health (NIH) is the largest public investor of biomedical research globally, investing more than $30 billion a year aiming to provide improved and affordable healthcare (NIH-Research, 2021). NIH-National Library of Medicine (NLM) maintains the comprehensive research publication source PubMed comprising more than 32 million citations for biomedical literature (NIH-NLM, 2021). Many MedAI systems rely upon scientific research publications in medicine as the primary data source for knowledge extraction.

If research gets manipulated through bogus, plagiarized, biased, or fraudulent conclusions, it turns into predatory research, potentially harming patients directly or indirectly. As per Wang et al., around 15% of retraction in biomedical Open Access Journals is due to fraudulent data (Wang et al., 2019). Anesthesiologist Scott Reuben and Family Medicine practitioner Anne Kirkman Campbell are few among many others to commit such frauds for money, fame.
and position, causing direct harm to patients including loss of lives (Borrell, 2009; Seife, 2021). Multiple studies about certain vaccines causing disorder in children baffled the medical community and the public for more than a decade (Rao and Andrade, 2011; Wakefield et al., 1998).

**Data Pollution in MedAI Solutions:** MedAI solutions, which utilize research literature as primary data input, are prone to data pollution. Passive data pollution attacks and active adversarial attacks can impact the integrity and security of MedAI solutions. Untargeted predatory publications induce passive data pollution, while an active adversarial attack is a targeted approach with deliberately poisoning the publication databases through specific predatory journals. Targeted and untargeted predatory publications can inject new data to poison the input dataset. We focus on existing and presumably untargeted data pollution, which can potentially influence the output of the MedAI.

**Our Contributions:** In this paper, we report on a novel case study of passive data pollution in MedAI solutions mediKanren (Patton et al., 2020), and CancerMine (Lever et al., 2019) to verify the vulnerability of research publications. To the best of our knowledge, this is a first study to explore the existing data pollution and demonstrate the threat in real-world MedAI solutions.

Our work casts serious doubt on whether research literature-based MedAI solutions are reliable enough to take chances with human lives. Moreover, our results show that MedAI may have no built-in logic to mitigate such threats.

**Why is this a Security Study?** Predatory research infiltration in MedAI solutions and its impact on MedAIs’ output is an exploitable vulnerability, which is new to the security community. While our study is an interdisciplinary effort, we believe that the security community should firsthand know the threat of research literature-based data pollution impacting MedAI solutions. The current and future MedAI systems may avoid these pitfalls if aware of the threats. We also contacted mediKanren team highlighting the underlying vulnerability.

## 2. Background

“Artificial Intelligence” (AI) in medicine is being employed in robotic procedures, diagnostics, statistics, and human biology, including omics (Hamet and Tremblay, 2017). Though it is still a far-fetched idea to replace the human touch in medicine, MedAI has opened possibilities to save on manual efforts and time to provide faster and adequate decision-making.

### 2.1. Health Care Revolution through MedAI

Around one in 10 Americans is affected by some rare disease, and 80% of around 7000 known rare diseases are genetics-based (NIH-RareDiseases, 2021). Orphan disease diagnosis may take from 1 to 5 years (Thoene, 2021) while rare diseases patients suffer from 40% wrong initial diagnosis and 5 to 30 years wait for correct diagnosis (Faurisson, 2004).

A 2021 data shows that 230 Startups are using AI in drug discovery to improve success rate significantly (Smith, 2017). A recent effort reported finding successful novel FDA-approved therapeutic recommendations for disorders ranging from undiagnosed and purely symptomatic disease to genetically diagnosed metabolic disorders (Shepard, 2021; Patton et al., 2020). In 2016, Wang et al. reported that pathology image-based MedAI could correctly identify metastatic breast cancer with 92% accuracy. A human expert could determine with 96% accuracy but applying both led to 99.5% accuracy (Wang et al., 2016). There is compelling evidence that MedAI can play a vital role in enhancing and complementing the ‘medical intelligence’ of the future clinician (Ramesh et al., 2004; NIH-RareDiseases, 2021).

### 2.2. Key Methodologies Adopted by MedAI

With advances in computational power and big data, machine learning (ML) is the most widely used AI component in MedAI solutions. Deep Learning (DL) and Natural Language Processing (NLP) are widely employed AI methods to extract meaningful information from the research literature. Artificial Neural networks and fuzzy logic combined as a hybrid intelligent system can accommodate common sense, extract knowledge from raw data, and use human-like reasoning mechanisms (NIH-AI, 2021). KGs are highly applicable in the medical domain and research as knowledge reasoning can find relationships among diagnosis, diseases, and treatments. Logical inference and probabilistic refinements can develop intelligent systems to suggest treatment options.
2.3. Security and Integrity of MedAI

Modern Healthcare solutions using AI look promising to save time, money, effort significantly, but the cost of “trusted but manipulated” information from such MedAI solutions is too high to ignore. Figure 1 depicts a high-level overview to show how predatory inputs can compromise a MedAI. An unreliable MedAI output can be fatal in clinical settings, and erroneous results can misalign the overall cycle of future research and healthcare solutions towards the harmful direction. Adversarial attacks on neural networks can cause errors in identifying cancer tumors and damage the confidence in MedAI output (Kotia et al., 2019). Szegedy et al. showed that very subtle adversarial inputs, which may not appear as pathological, can potentially change the output (Leung et al., 2015). A critical insight into why adversarial examples exist is that, given any dataset, the attacker can potentially perturb it in a direction that aligns well with the weights of the MedAI algorithm and thus amplifies its effect on the output (Goodfellow et al., 2014). As NLP is the core process to extract intelligent information from the research literature for MedAI, a robust and efficient algorithm against NLP adversarial attacks is a necessity rather than preference (Zhang et al., 2020). MedAI aims to bring all the relevant data together and filter out irrelevant information without skipping more challenging instances. It is crucial for MedAI, especially in rare diseases, to include that one paper with the latest finding that may alter the life for some patient(s), and it is even more critical to validate if that paper is predatory or not.

A real challenge is maintaining the integrity and security of research data as the basis of MedAI in Precision Medicine and not letting it be Predatory Medicine. Our study highlights the vulnerability of polluted input through predatory publications that may have the potential to generate unreliable MedAI output, especially in finely targeted scenarios of Precision Medicine.

3. Predatory Research

Medical research has been revolutionary in the past few years, but innovation is not the only reason for the high volume of research publications. ‘Publish or Perish’ culture puts enormous pressure on budding scientists and researchers to publish their research (Rawat and Meena, 2014). Publications and citations are being used as a metric for progressing towards the doctorate, employment, promotions, and grants/funding by state and federal agencies. Opportunists may exploit these trends for their benefit to lure easy targets looking for some publication credits (Rawat and Meena, 2014). Research misconduct is an even more significant threat to pollute the research repositories (Smith, 2006; Wang et al., 2017,
Misleading conclusions may go undetected for an extended period and may affect clinical practices before being retracted (Budd et al., 1999). Accommodating information from heterogeneous sources is vital in MedAI decision-making; it also enables predatory research to get mixed with the authentic inputs.

3.1. What is a Predatory Journal?
Currently, the characteristics of predatory journals have not been standardized nor broadly accepted by the research community. The majority of potential predatory journals have absent or minimal peer-review process (Bartholomew, 2014; Richtig et al., 2018) and follow questionable practices focusing on ‘pay to publish’ model (Richtig et al., 2018). With a possibility of having plagiarized, incorrect, fake data and manipulated results, predatory journals are, in fact, increasingly interfering with genuine research. Jeffrey Beall was first to raise the concern around 2008 and maintained a list of potentially predatory journals. DOAJ, Cabell’s list, and other independent online resources are reference points to identify potentially predatory journals (Stop-Predatory-Journals, 2021; Grudniewicz et al., 2019; DOAJ, 2021). In the absence of any standard definition, we rely on the current list of potential predatory journals from these resources to apply in this work.

3.2. How Big is Predatory Research?
Beall identified few potential predatory publishers in 2011, and by 2015, there were estimated as many as 10,000 predatory journals worldwide (Shen and Bjork, 2015). The ultimate risk is the altered results of synthesized research because of rapidly increasing numbers of such predatory publications (Cobey et al., 2018; Bartholomew, 2014). There have been efforts to expose such practices of accepting fake papers, recruiting fake editors, but numbers are rising every year (Ivan, 2013; Piotr Sorokowski, 2017). A genuine concern is that there are more suspected predatory journals (10,406) than legitimate journals (10,077) in Cabell’s list (Grudniewicz et al., 2019).

3.3. PPP Infiltration in Trusted Resources
The question is whether credited research resources like PubMed are already infected with predatory publications or not. Manca et al. reported the possible infiltration of predatory research in PubMed (Manca et al., 2018). European databases also carry predatory journals and research shows that predatory journals get even more publications than non-predatory journals after being listed in a reputed database (Perlin et al., 2018).

4. Studied MedAI Solutions
In this work, we focus on research literature based clinical MedAI solutions, which can impact patients directly. We study two MedAI solutions mediKanren and CancerMine with different AI approaches, data processing, and output representation (Patton et al., 2020; Lever et al., 2019). Both studied MedAI solutions heavily rely on research literature inputs, primarily from PubMed. mediKanren has a broad scope of drug repurposing to treat newly diagnosed or unknown diseases based on inferred relationships. CancerMine aims to help with the early diagnosis of cancer type based on patients’ genetic profiles.

4.1. mediKanren
mediKanren is a MedAI employing logical reasoning over the NIH SemMedDB and translational knowledge graphs to reduce the cost of drug discovery and repurposing (Windsor, 2021). mediKanren is an implementation of miniKanren (Logic Programming Language), Racket (General-purpose Programming Language), Pubmed-derived SemMedDB, NIH translational KGs, and a graphical user interface (GUI) to simplify data exploration to assist Precision Medicine (Patton et al., 2020). mediKanren also utilizes KGs with the standardized structure to improve interoperability, ingesting and processing new data from different sources. CURIE (Compact Uniform Resource Identifier), Concept Normalization, and KGs are the basis of mediKanren’s functionality.

We study state-of-the-art mediKanren prototypes, code and biolink (GitHub-mediKanren, 2021). mediKanren is currently under real-world stress-testing, which makes it relevant to study for the existing exploitable vulnerabilities (Shepard, 2021).

4.2. CancerMine
CancerMine is an automated text-mining approach for extracting gene-disease relationships from PubMed literature to reduce the manual effort and cost of providing timely diagnosis and treatment (Singhal et al., 2016). CancerMine pro-
Table 1: Selected 25 Concepts, covering pandemics, common, and rare diseases, to analyze mediKanren prototype ‘code’ vulnerability to PPP

| Concept Name                              | Query Term                                                                 | Category | Type       |
|-------------------------------------------|-----------------------------------------------------------------------------|----------|------------|
| ADNP                                      | ADNP, Helsmoortel-VanDerAa Syndrome, HVDAS                                  | very rare | disease    |
| Adenoid Cystic Carcinoma                  | Adenoid Cystic Carcinoma, cylindroma                                         | rare     | disease    |
| BCR                                       | BCR                                                                         | common   | gene       |
| Cervical Cancer                           | Cervical cancer                                                             | rare     | disease    |
| Colorectal Cancer                         | Colorectal cancer, colon cancer, rectal cancer                              | common   | disease    |
| Coronavirus                               | Coronavirus, HCoV-OC43, SARS-CoV-2                                          | pandemic | virus      |
| Curcumin                                  | Curcumin, Diferuloylmethane, Turmeric                                        | common   | substance  |
| Dravet Syndrome                           | Dravet Syndrome, Severe myclonic epilepsy of infancy, SMEI                   | very rare | disease    |
| Ebola                                     | Ebola, rVSV-ZEBOV, ebola virus                                              | pandemic | virus      |
| Epithelial Mesenchymal Transition         | Epithelial-mesenchymal transition, epithelial mesenchymal transition.        | common   | cell       |
| Gastric Carcinoma                         | Gastric Carcinoma, Gastric Cancer, Stomach Cancer                           | rare     | disease    |
| Imatinib                                  | Imatinib, Imatinib mesylate                                                 | common   | drug       |
| Ischemic Stroke                           | Ischemic stroke                                                             | common   | disease    |
| Malaria                                   | Malaria, Plasmodium berghei, Plasmodium falciparum                          | rare     | disease    |
| Methyltransferase                         | Methyltransferase                                                           | common   | disease    |
| MIR-200                                   | MIR-200, MicroRNA-200                                                       | common   | gene       |
| Neuroblastoma                             | Neuroblastoma, myrca                                                        | very rare | disease    |
| Neuroendocrine Prostate Cancer            | neuroendocrine prostate cancer                                              | rare     | disease    |
| Non-Small Cell Lung Cancer                | Non-small cell lung cancer, NSCLC                                            | common   | disease    |
| Ovarian cancer                            | Ovarian cancer, germ cell cancer, germ cell tumor                           | rare     | disease    |
| Pancreatic Cancer                         | Pancreatic cancer, Pancreatic neuroendocrine                                 | rare     | disease    |
| Prostate Cancer                           | Prostate cancer                                                             | common   | disease    |
| T-Cell                                    | T-Cell, t cells, Chimeric Antigen Receptor                                  | common   | cell       |
| Triple Negative Breast Cancer             | Triple negative breast cancer                                               | rare     | disease    |
| Tyrosine Kinase                           | Tyrosine, Tyrosine Kinase                                                   | common   | Protein    |

CancerMine inputs and outputs in TSV/CSV file formats were analyzed using MS Excel.

5.1. Key Terms and Definitions

Each article on PubMed has a unique identifier called PMID (PubMed ID). In this work, we are using the SemMedDB (semmedVER40_R), with PubMed data processed up to June 30, 2018.

NIH defines a rare disease as a condition that affects fewer than 200,000 people in the US. A rare disease is known as an orphan disease if drug companies are not interested in developing treatments (NIH-RareDiseases, 2021; Thoene, 2021). Concept is defined as a unique medical term as per NIH Unified Medical Language System (UMLS) Metathesaurus, and CUI is the Concept Unique Identifier (Bodenreider, 2004). PREDICATE is the representation of the relationship between any two medical concepts identified as SUBJECT and OBJECT. For example, Imatinib (SUBJECT) Treats (PREDICATE) Mastocytosis (OBJECT). Compact Uniform Resource Identifiers (CURIEs) serve as machine-readable markers for different databases. Graph vertices represent medical...
6. Data Extraction

We extracted a set of predatory journals based on Beall’s list\(^1\) and compared with more current list\(^2\). We created an advanced query with the list of existing predatory journals in PubMed, and downloaded the metadata for 47,051 predatory publications. We extracted 8,289 retracted publications from PubMed with “Retraction of publication [Publication Type]”, a query adopted from Budd et al. (1999).

6.1. mediKanren Data Inputs

We study 25 concepts to study in this work under common, rare, very rare, and pandemic categories to see the extent of PPP in diverse scenarios. For each of these 25 concepts, we extracted the set of 200 rows (100 rows of predatory PMIDs and 100 rows of non-predatory PMIDs) from the PREDICATION table of SemMedDB. A .csv file was prepared for each concept except for a few rare concepts with less than 200 publications. Table 1 provides details of the selected concepts.

Prototype biolink is currently utilizing data inputs from four NIH translational knowledge graphs RoboKop, SemMed, Orange, and Rtx. mediKanren team provided the local copy of NIH KGs employed in biolink. We applied python scripts to extract PMIDs from applied NIH Translational KGs to study the presence of predatory PMIDs.

6.2. CancerMine Data Inputs

We utilized data from CancerMine Zenodo repository. The primary raw input cancermine_unfiltered.tsv is processed to create other two main inputs as cancermine_collated.tsv and cancermine_sentences.tsv. cancermine_collated.tsv contains the cancer gene roles supporting citation counts, and cancermine_sentences.tsv carries the sentences for the cancer gene roles. This SENTENCE file contains information on the source publication (e.g., journal, publication date, etc.), the actual sentence, and the cancer type, gene, and role extracted from the sentence.

7. Passive Data Pollution Verification

Based on our hypothesis, PubMed has existing data pollution with the predatory publications, and MedAI solutions use this polluted dataset. Other than predatory journal publications, the PubMed-derived database also carries the retracted research publications. To verify PPP in SemMedDB tables, we queried restructured SemMedDB on HPC to find predatory PMIDs.

For mediKanren prototype ‘code’, we run each concept-specific CSV file through Racket commands to pre-process the input. We execute all the end-user queries on Racket ver 7.4 and gui-simple.rkt file as working GUI for code prototype of mediKanren. ‘Biolink’ prototype works with gui_simple_v3.rkt GUI on KGs, and we run sample queries to verify the data pollution in the input and output of the studied MedAI solutions.

For CancerMine, we verified the overall PPP in provided datasets from their repositories, queried online tool, and downloaded data to verify the PPP in tool-provided subsets. We utilized the same set of predatory PMIDs extracted from PubMed for mediKanren and CancerMine PPP verification.

8. Results

Our results show that predatory publications have a significant presence in the research literature repository PubMed (47,051 predatory publications). Results also validate that predatory research can traverse from PubMed to MedAI output. For detailed analysis, we organize our results into five subsections: (1) PPP in SemMedDB; (2) Retracted publications in SemMedDB; (3) PPP in NIH Translational KGs; (4) PPP in mediKanren GUI output; and (5) PPP in CancerMine.

8.1. PPP in SemMedDB

The PREDICATION table is carrying concept, sentence ID, predicate, SUBJECT_CUI, and OBJECT_CUI. Although predatory PMIDs numbers seem smaller compared to the huge dataset size, the fraction holds a large number (44,665) of predatory publications. Table 2 shows the overall PPP infiltration in SemMedDB tables.

---

1. Beall’s list of potential predatory journals and publishers.
2. Web Archives-predatoryjournals.com.
Table 2: PPP in SemMedDB Tables

| SemMed Table | Total Rowcount | PPP Rowcount |
|--------------|----------------|--------------|
| PREDICATION  | 97,772,561     | 256,641      |
| SENTENCE     | 187,449,479    | 357,484      |
| CITATION     | 1,369,837,426  | 2,735,289    |

Table 3: SemMedDB: PPP For Studied 25 Concepts

| Concept                  | Category   | PPP  |
|--------------------------|------------|------|
| ADNP                     | very rare  | 5    |
| Adenoid Cystic Carcinoma | rare       | 51   |
| BCR                      | common     | 659  |
| Cervical Cancer          | rare       | 1,005|
| Colorectal Cancer        | common     | 5,510|
| Coronavirus               | pandemic   | 6    |
| Curcumin                 | common     | 500  |
| Dravet Syndrome          | very rare  | 1    |
| Ebola                    | pandemic   | 15   |
| Epithelial Mesenchymal Transition | common | 679  |
| Gastric Carcinoma        | rare       | 3,727|
| Imatinib                 | common     | 424  |
| Ischemic Stroke          | common     | 260  |
| Malaria                  | rare        | 252  |
| Methyltransferase        | common     | 52   |
| MIR-200                  | common     | 309  |
| Neuroblastoma            | very rare  | 1,209|
| Neuroendocrine Prostate Cancer | rare | 11   |
| Non-small-cell Lung Cancer | common   | 4,414|
| Ovarian Cancer           | rare       | 2,718|
| Pancreatic Cancer        | rare       | 2,139|
| Prostate cancer          | common     | 3,849|
| T-Cell                   | common     | 4,376|
| Triple Negative Breast Cancer | rare | 246  |
| Tyrosine Kinase          | common     | 2,061|

Table 4: PPP in NIH Translational KGs

| Database | Total Rowcount | PPP Rowcount |
|----------|----------------|--------------|
| Robokop  | 5,367,905      | 5,676        |
| SemMed   | 44,245,576     | 164,324      |
| Orange   | 836,118        | 287          |
| Rtx      | 7,664          | 99           |

8.2. Retracted Publications in SemMedDB

We also verified the PPP in SemMedDB for all 25 selected concepts in this work. PPP count varies from under 5 (very rare diseases: Dravet Syndrome, ADNP) to around 5000 or more (common cancer: Non-small-cell Lung Cancer, Colorectal Cancer). We can see that PPP is higher, in general, for common diseases, and lower for rare and very rare diseases, but also higher PPP for rare diseases like Gastric Carcinoma. We did not analyze the percentage of concept-specific PPP for these 25 concepts as any presence may be damaging for a specific scenario. Table 3 shows the PPP count in SemMedDB for all 25 concepts studied in this work.

8.3. PPP in NIH Translational KGs

mediKanren prototype ‘biolink’ can create and run queries on translational KGs to deliver the suggestions in a comprehensible manner (Windsor, 2021). Table 4 shows the PPP in all four translational KGs. Percentage of PPP in these KGs does not appear huge, but PPP is significant, especially in the largest KG SemMed. For example, KG Rtx is with the most significant percentage of 1.3 with a smaller PPP (99). KG SemMed shows a smaller percentage (.37) with a much higher PPP (164,324). This observation also validates that even a lower number with a high percentage on any concept will have a higher probability to appear in MedAI output.

8.4. PPP in mediKanren GUI Output

Specific input datasets for 25 concepts are fed independently to mediKanren prototype code to analyze targeted queries to follow the Precision Medicine approach. We executed multiple queries on each concept for different triples of Subject_CUI, Object_CUI, and Predicate. We found that majority of queries show predatory PMID(s) in mediKanren GUI output. Figure 2 shows non-predatory PMIDs appearing in mediKanren prototype code. For example, the only PMID returned for concept Non-small-cell lung cancer and predicate AFFECTS is predatory PMID, and for predicate PROCESS_OF output contains both predatory and non-predatory PMIDs.

Table 5 shows 25 representative cases for 25 concepts validating the problem of PPP traversing from PubMed to MedAI output. Data demonstrates that mediKanren may pick predatory PMIDs for common as well as for rare diseases if predatory PMIDs are present in the inputs.

PPP in SemMedDB can affect the MedAI outcome even with a low number of predatory PMIDs. If a particular case has only a few publications on a specific concept, and there are more predatory than non-
**Figure 2:** mediKanren ‘code’ GUI [Concept, Predicate and Object- yellow; Predatory PMIDs - red]

**Table 5:** PPP in MediKanren ‘code’ GUI Output with Predatory and Non-predatory PMIDs

| Concept Name                                      | (Subject_CUI, Object_CUI, Predicate)                              | Pred | Non-Pred | Total |
|--------------------------------------------------|------------------------------------------------------------------|------|----------|-------|
| ADNP                                             | (1334473, 3394, INTERACTS_WITH)                                  | 1    | 0        | 1     |
| Adenoid Cystic Carcinoma                         | (10086, 30705, PROCESS_OF)                                       | 3    | 2        | 5     |
| BC01                                             | (812383, 915089, COEXISTS_WITH)                                  | 1    | 0        | 1     |
| Cervical Cancer                                  | (7847, 30705, PROCESS_OF)                                        | 4    | 6        | 10    |
| Colorectal Cancer                                | (7102, 27661, AFFECTS)                                           | 1    | 0        | 1     |
| Coronavirus                                      | (10076, 15576, PROCESS_OF)                                       | 1    | 0        | 1     |
| Curcumin                                         | (10487, 6826, AFFECTS)                                           | 1    | 0        | 1     |
| Dravet Syndrome                                 | (10487, 6826, AFFECTS)                                           | 1    | 0        | 1     |
| Ebola                                            | (25594032)                                                       | 1    | 3        | 4     |
| Epithelial Mesenchymal Transition                | (14609, 346109, LOCATION_OF)                                    | 1    | 0        | 1     |
| Gastric Carcinoma                                | (24623, 30705, PROCESS_OF)                                       | 2    | 5        | 7     |
| Imatinib                                         | (935989, 23437, TREATS)                                          | 5    | 3        | 8     |
| Ischemic Stroke                                  | (948008, 30705, PROCESS_OF)                                       | 7    | 4        | 11    |
| Malaria                                          | (24530, 21311, ISA)                                              | 1    | 2        | 3     |
| Methyltransferas                                 | (25831, 11315, PART_OF)                                          | 1    | 0        | 1     |
| MH-200                                           | (1537849, 13081, AFFECTS)                                        | 1    | 0        | 1     |
| Neuroblastoma                                    | (27819, 27661, ISA)                                              | 2    | 2        | 4     |
| Neuroendocrine Prostate Cancer                   | (936223, 30705, PROCESS_OF)                                      | 1    | 1        | 2     |
| Non-Small Cell Lung Cancer                       | (7131, 30705, NEG_PROCESS_OF)                                    | 7    | 4        | 11    |
| Ovarian cancer                                   | (29925, 1520166, PROCESS_OF)                                     | 1    | 1        | 2     |
| Pancreatic Cancer                                | (235974, 30705, PROCESS_OF)                                      | 2    | 2        | 4     |
| Prostate Cancer                                  | (376358, 30705, PROCESS_OF)                                       | 5    | 6        | 11    |
| T-Cell                                           | (25594032)                                                       | 1    | 0        | 1     |
| Triple Negative Breast Cancer                    | (6142, 30705, PROCESS_OF)                                        | 3    | 3        | 6     |
| Tyrosine Kinase                                  | (206384, 27651, ASSOCIATED_WITH)                                  | 1    | 0        | 1     |
predatory, that may mislead the decision. For example, the concept *Imatinib* for predicate *TREATS* returns five predatory and three non-predatory PMIDs from a pool of 200 rows (100 predatory PMIDs and 100 non-predatory PMIDs). MediKanren GUI showed clear evidence of picking up predatory PMIDs in output with targeted input datasets.

For mediKanren prototype *biolink*, we queried the whole input for all four KGs without any specific test sampling. Figure 3 shows that predatory/ non-predatory PMIDs are appearing in prototype biolink’s output.

We did not verify the presence of retracted PMIDs in mediKanren GUI output in this work. However, based on the working logic, MedAI is expected to pick any present publication (predatory or non-predatory) for a specific user query.

8.5. PPP in CancerMine

We analyze CancerMine data directly downloaded from the data repository and downloaded output files from online queries on the CancerMine web tool. Table 6 shows that overall predatory PMIDs have above 5% in raw data and extracted Sentence CSV file for cancer type and gene relationship. We observe that 51.64% of predatory PMIDs have a prediction probability of 0.7 and higher (max is .9997), indicating the role of these publications on overall prediction.

| Table 6: PPP in CancerMine Dataset |
|------------------------------------|
|                                | unfiltered tsv | sentences tsv |
|----------------------------------|----------------|---------------|
| Total PMIDs                      | 172,443        | 55,881        |
| PPP                              | 9,479          | 2,874         |
| PPP %                            | 5.50%          | 5.14%         |
| Unique PMIDs                     | 73,099         | 35,623        |
| Unique PPP                       | 3,384          | 1,637         |
| PPP %                            | 4.63%          | 4.60%         |
probability. We downloaded raw data from the CancerMine repository to carry 455 cancer types, and 150 out of 455 types show predatory PMIDs. Breast cancer shows the highest number of predatory PMIDs.

We cross-referenced the specific gene-cancer-role details from the CancerMine data repository and application output downloads. We observe PPP in multiple subsets of targeted queries regarding a particular cancer type, gene, and role of the gene. Table 7 is presenting PPP for few other cancer-gene-role triples of selected cancer types. We selected these cancer types similar to some concepts explored for other MedAI mediKanren in this work. PPP can be much higher on a particular cancer-gene-triple. For example, Neuroblastoma-Driver-MYCN filters a set of 164 PMIDs, and 20.12% (33) PMIDs are predatory. Another case of Stomach cancer-Tumor_Suppressor-TFF1 is a much smaller set of 16 PMIDS with 25% (4) predatory PMIDs.

We successfully show these predatory PMIDs in the input sources (SemMedDB and CancerMine datasets) and the output (mediKanren GUI output and CancerMine website downloaded output), which verifies the existing threat in real-life research-literature-based MedAI solutions. Though we are not exploring the threat of ML manipulation in this work, it may be possible to analyze predatory publications’ impact on shifting prediction probability.

9. Limitations and Challenges

Though our work clearly shows the infiltration of PPP in PubMed and affecting the output of mediKanren GUI, there are several factors to limit the outcome of this study. One of the challenges is determining the valid list of all known predatory journals at any given point in time.

The frequency of derived database updates also can affect the PPP. All the mediKanren queries for the code prototype are executed with targeted much smaller datasets for selected concepts to highlight the threat. We believe that results will be comparable even if we execute queries on the whole dataset.

This work only focuses on the existing PPP verification without any current analysis of data training and prediction probability affected by PPP.

10. Discussion and Future Work

As observed in our study, MedAI relies on the credibility of the reputed data source. There is no in-built defense logic in both the studied MedAI solutions to minimize the threat of predatory research influencing the output. Our work indicates the need to have a better defense system at the source level to minimize the threat of data pollution.

We shared our findings and concerns with the mediKanren team. The mediKanren team has acknowledged the threat and is looking into the issue. Though this work is specific to research literature-based clinical MedAI solutions, we looked at other current state-of-the-art solutions for existing defense strategies towards predatory science, if any exists. Iris.ai is specific for researchers to provide relevant research literature based on the research hypothesis. We observed predatory publications in iris.ai results as well, and the iris.ai team also confirmed not to have any current defense mechanism to filter out potential predatory research (IRIS.AI, 2021).

Though currently not explored but in a possible adversarial attack scenario, in near future, it can be viable to produce targeted predatory publications in bulk through new-age NLP text-generator tools like GPT-3 (Brown et al., 2020; GPT3, 2021). A targeted adversarial attack on a rare disease can make it look valid while injecting fake data with alternative conclusions. This approach may impact rare and unknown diseases scenarios more as there is little available research to cross-validate.

Approximately 50% medical providers showed concern about producing fatal errors and technical/operational glitches. These concerns resonate with the known ethical and regulatory challenges with MedAI solutions involving privacy, data integrity, accessibility, accountability, transparency, and liability (AI, 2018; Vayena et al., 2018).

In the age of social media and web-based information, the future trustworthy information extraction will have more significant challenges and higher stakes. Future work will further study the impact of predatory research, including retracted publication on MedAI solutions. We plan to look at other security vulnerabilities to better defend against information pollution.

11. Conclusion

Our work concludes that polluted inputs can cause a possible failure of any MedAI to deliver the intended output. Predatory research is on the rise and may further degrade research literature-based MedAI solutions’ credibility. Studied MedAI solutions treat all
research data as trusted and do not consider predatory research-induced data pollution. In the absence of any defense, MedAI solutions may produce unreliable output. Existing data pollution fuels motivation for more targeting attacks.

Our study shows clear evidence of how predatory research information is navigating through publication channels and eventually may alter patient care decisions if used in the clinical settings without resolving the existing threat of predatory research intrusion. We are confident that verifying the vulnerabilities early in the process will contribute in developing more robust solutions for taking Precision Medicine to the next level in broader settings.

Institutional Review Board (IRB)
This research did not require IRB approval.

Acknowledgments
We thank Matthew Might and Michael J Patton from the mediKanren team for assisting with a local copy of translational datasets and useful insights.

References
Intel AI. Overcoming barriers in ai adoption in healthcare, 2018. https://newsroom.intel.com/wp-content/uploads/sites/11/2018/07/healthcare-iot-infographic.pdf.

Robert E Bartholomew. Science for sale: the rise of predatory journals. Journal of the Royal Society of Medicine, 107(10):384, 2014.

Olivier Bodenreider. The unified medical language system (umls): integrating biomedical terminol-
Geoffrey S Ginsburg and Kathryn A Phillips. Precision medicine: from science to value. *Health Affairs*, 37(5):694–701, 2018.

GitHub-mediKanren, 2021. https://github.com/webyrd/MediKanren.

Ian J Goodfellow, Jonathon Shlens, and Christian Szegedy. Explaining and harnessing adversarial examples. *arXiv preprint arXiv:1412.6572*, 2014.

GPT3. Text-generating algorithm from openai, 2021. https://www.digitaltrends.com/features/openai-gpt-3-text-generation-ai/.

Agnes Grudniewicz, David Moher, Kelly D Cobey, Gregory L Bryson, Samantha Cukier, Kristiann Allen, Clare Ardern, Lesley Balcom, Tiago Barrros, Monica Berger, et al. Predatory journals: no definition, no defence, 2019.

Pavel Hamet and Johanne Tremblay. Artificial intelligence in medicine. *Metabolism*, 69:S36–S40, 2017.

IRIS.AI, 2021. https://iris.ai/.

Oransky Ivan. Science reporter spoofs hundreds of open access journals with fake papers, October 2013. https://retractionwatch.com/2013/10/03/science-reporter-spoofs-hundreds-of-journals-with-a-fake-paper/, Accessed on 02.24.2021.

Jai Kotia, Adit Kotwal, and Rishika Bharti. Risk susceptibility of brain tumor classification to adversarial attacks. In *International Conference on Man–Machine Interactions*, pages 181–187. Springer, 2019.

Michael KK Leung, Andrew Delong, Babak Alipanahi, and Brendan J Frey. Machine learning in genomic medicine: a review of computational problems and data sets. *Proceedings of the IEEE*, 104 (1):176–197, 2015.

Jake Lever, Eric Y Zhao, Jasleen Grewal, Martin R Jones, and Steven JM Jones. Cancermine: a literature-mined resource for drivers, oncogenes and tumor suppressors in cancer. *Nature methods*, 16(6):505–507, 2019.

Andrea Manca, David Moher, Lucia Cugusi, Zeevi Dvir, and Franca Deriu. How predatory journals leak into pubmed. *CMAJ*, 190(35):E1042–E1045, 2018.

NIH-AI. NIH-Artificial Intelligence, Machine Learning, and Deep Learning, 2021. https://www.nibib.nih.gov/research-funding/machine-learning.

NIH-NLM. Pubmed- biomedical research literature database, 2021. https://pubmed.ncbi.nlm.nih.gov/.

NIH-RareDiseases. Genetic and rare diseases information center (gard)–an ncats program, 2021. https://rarediseases.info.nih.gov/.

NIH-Research, 2021. https://www.nih.gov/about-nih/what-we-do/impact-nih-research, Accessed online on 05/07/2021.

M Patton, G Rosenblatt, W Byrd, and M Might. medikanren: A system for bio-medical reasoning, 2020. http://minikanren.org/workshop/2020/minikanren-2020-paper10.pdf/.

Marcelo S Perlin, Takeyoshi Imasato, and Denis Borenstein. Is predatory publishing a real threat? evidence from a large database study. *Scientometrics*, 116(1):255–273, 2018.

Agnieszka Sorokowska & Katarzyna Pisanski Piotr Sorokowski, Emanuel Kulczycki. Predatory journals recruit fake editor, March 2017. https://www.nature.com/news/predatory-journals-recruit-fake-editor-1.21662.

AN Ramesh, Chandra Kambhampati, John RT Monson, and PJ Drew. Artificial intelligence in medicine. *Annals of the Royal College of Surgeons of England*, 86(5):334, 2004.

TS Sathyanarayana Rao and Chittaranjan Andrade. The mmr vaccine and autism: Sensation, refutation, retraction, and fraud. *Indian journal of psychiatry*, 53(2):95, 2011.

Seema Rawat and Sanjay Meena. Publish or perish: Where are we heading? *Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences*, 19(2):87, 2014.

G Richtig, M Berger, B Lange-Asschenfeldt, W Aberer, and E Richtig. Problems and challenges of predatory journals. *Journal of the European Academy of Dermatology and Venereology*, 32(9):1441–1449, 2018.
Charles Seife. Research misconduct identified by the US Food and Drug Administration—out of sight, out of mind, out of the peer-reviewed literature, 2021. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2109855.

Cenyu Shen and Bo-Christer Bjork. Predatory open access: a longitudinal study of article volumes and market characteristics. *BMC medicine*, 13(1):1–15, 2015.

B. Shepard. Diagnosis in 2.127 seconds: Solving a years-long vomiting mystery using AI, research and brain power - news, 2021. https://www.uab.edu/news/health/item/10703-diagnosis-in-2-127-seconds-solving-a-years-long-vomiting-mystery-using-ai-research-and-brain-power.

Shetty. A promising step forward for predicting lung cancer, May 2019. https://www.blog.google/technology/health/lung-cancer-prediction/.

Hardeep Singh, Gordon D Schiff, Mark L Graber, Igho Onakpoya, and Matthew J Thompson. The global burden of diagnostic errors in primary care. *British Medical Journal quality & safety*, 26(6):484–494, 2017.

Ayush Singhal, Michael Simmons, and Zhiyong Lu. Text mining genotype-phenotype relationships from biomedical literature for database curation and precision medicine. *PLoS computational biology*, 12(11):e1005017, 2016.

Richard Smith. Research misconduct: the poisoning of the well. *Journal of the Royal Society of Medicine*, 99(5):232–237, 2006.

Simon Smith. 230 startups using artificial intelligence in drug discovery, 2017. https://blog.benchsci.com/startups-using-artificial-intelligence-in-drug-discovery.

Stop-Predatory-Journals. List of predatory publishers, 2021. https://web.archive.org/web/2021122200383562/https://predatoryjournals.com/journals/, original site went down after Dec 20, 2021.

Ali S Saber Tehrani, HeeWon Lee, Simon C Mathews, Andrew Shore, Martin A Makary, Peter J Pronovost, and David E Newman-Toker. 25-year summary of US malpractice claims for diagnostic errors 1986-2010: an analysis from the national practitioner data bank. *BMJ quality & safety*, 22(8):672–680, 2013.

Crooks Thoene. Report of the national commission on orphan diseases—February 1989, 2021. https://rarediseases.info.nih.gov/files/report_of_the_national_commission_on_orphan_diseases_february_1989.pdf.

Effy Vayena, Alessandro Blasimme, and I Glenn Cohen. Machine learning in medicine: addressing ethical challenges. *PLoS medicine*, 15(11), 2018.

Andrew J Wakefield, Simon H Murch, Andrew Anthony, John Linnell, David M Casson, Mohsin Malik, Mark Berelowitz, Amar P Dhillon, Michael A Thomson, Peter Harvey, et al. Retracted: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children, 1998.

Dayong Wang, Aditya Khosla, Rishab Gargeya, Humayun Irshad, and Andrew H Beck. Deep learning for identifying metastatic breast cancer. *arXiv preprint arXiv:1606.05718*, 2016.

Justin Wang, Jerry C Ku, Naif M Alotaibi, and James T Rutka. Retraction of neurosurgical publications: a systematic review. *World neurosurgery*, 103:809–814, 2017.

Tao Wang, Qin-Rui Xing, Hui Wang, and Wei Chen. Retracted publications in the biomedical literature from open access journals. *Science and engineering ethics*, 25(3):855–868, 2019.

Matt Windsor. A ‘high-speed Dr. House’ for medical breakthroughs, 2021. https://www.uab.edu/news/research/item/10382-a-high-speed-dr-house-for-medical-breakthroughs.

Wei Emma Zhang, Quan Z Sheng, Ahoud Alhazmi, and Chenliang Li. Adversarial attacks on deep-learning models in natural language processing: A survey. *ACM Transactions on Intelligent Systems and Technology (TIST)*, 11(3):1–41, 2020.